{{Rsnum
|rsid=1328674
|Gene=HTR2A
|Chromosome=13
|position=46867572
|Orientation=minus
|GMAF=0.0528
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=HTR2A
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 6.2 | 92.9
| HCB | 0.0 | 8.1 | 91.9
| JPT | 0.0 | 6.2 | 93.8
| YRI | 0.7 | 18.6 | 80.7
| ASW | 1.8 | 10.5 | 87.7
| CHB | 0.0 | 8.1 | 91.9
| CHD | 0.0 | 7.4 | 92.6
| GIH | 0.0 | 4.0 | 96.0
| LWK | 0.9 | 13.9 | 85.2
| MEX | 0.0 | 7.0 | 93.0
| MKK | 0.6 | 9.1 | 90.3
| TSI | 0.0 | 9.9 | 90.1
| HapMapRevision=28
}}[[rs1328675]] is part of a 4-SNP haplotype in the serotonin 2A receptor gene [[HTR2A]] that has been associated with [[rheumatoid arthritis]] in a study of 1800 European patients. The risk allele is [[rs1328674(A)]] in dbSNP orientation. The overall risk for the haplotype CTCC of SNPs [[rs6311]]-[[rs1328674]]-[[rs6313]]-[[rs6314]] is 1.68 (CI: 1.20 - 2.34, p = 0.02). This is actually quite close to the odds ratio calculated for [[rs1328674]] by itself; OR of 1.62 (p = 0.007). {{PMID|18006541}}

Note: the orientation of [[rs1328674]] in dbSNP is opposite that cited by this publication; therefore, with respect to dbSNP, the haplotype of risk as cited above should be CACC, rather than CTCC as published.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}